NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $6.68 -0.05 (-0.74 %) (As of 07/15/2018 03:24 PM ET)Previous Close$6.68Today's Range$6.68 - $6.8452-Week Range$4.34 - $7.66Volume1.38 million shsAverage Volume2.21 million shsMarket Capitalization$1.45 billionP/E Ratio-18.05Dividend YieldN/ABeta1.38 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. Receive TXMD News and Ratings via Email Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:TXMD CUSIPN/A Webwww.therapeuticsmd.com Phone561-961-1900 Debt Debt-to-Equity RatioN/A Current Ratio7.61 Quick Ratio7.51 Price-To-Earnings Trailing P/E Ratio-18.05 Forward P/E Ratio-13.10 P/E GrowthN/A Sales & Book Value Annual Sales$16.78 million Price / Sales86.22 Cash FlowN/A Price / CashN/A Book Value$0.60 per share Price / Book11.13 Profitability EPS (Most Recent Fiscal Year)($0.37) Net Income$-76,920,000.00 Net Margins-483.98% Return on Equity-66.77% Return on Assets-60.12% Miscellaneous Employees173 Outstanding Shares216,580,000Market Cap$1,446.78 TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions What is TherapeuticsMD's stock symbol? TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD." How were TherapeuticsMD's earnings last quarter? TherapeuticsMD Inc (NASDAQ:TXMD) posted its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.11) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The firm earned $3.77 million during the quarter, compared to analyst estimates of $4.18 million. TherapeuticsMD had a negative net margin of 483.98% and a negative return on equity of 66.77%. The firm's revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.11) earnings per share. View TherapeuticsMD's Earnings History. What price target have analysts set for TXMD? 9 analysts have issued 12 month target prices for TherapeuticsMD's stock. Their forecasts range from $6.00 to $28.00. On average, they expect TherapeuticsMD's share price to reach $14.6250 in the next year. This suggests a possible upside of 118.9% from the stock's current price. View Analyst Ratings for TherapeuticsMD. What is the consensus analysts' recommendation for TherapeuticsMD? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting TherapeuticsMD? TherapeuticsMD saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 59,072,667 shares, an increase of 1.0% from the June 15th total of 59,676,731 shares. Based on an average trading volume of 2,582,333 shares, the short-interest ratio is presently 22.9 days. Currently, 34.0% of the company's shares are short sold. View TherapeuticsMD's Current Options Chain. Who are some of TherapeuticsMD's key competitors? Some companies that are related to TherapeuticsMD include Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), Agios Pharmaceuticals (AGIO), GALAPAGOS NV/S (GLPG), Ligand Pharmaceuticals (LGND), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Array Biopharma (ARRY). Who are TherapeuticsMD's key executives? TherapeuticsMD's management team includes the folowing people: Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)Mr. Daniel Alan Cartwright, CFO, Treasurer & Principal Accounting Officer (Age 60)Mr. Mitchell L. Krassan, Chief Strategy Officer and Exec. VP (Age 52) Has TherapeuticsMD been receiving favorable news coverage? Headlines about TXMD stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a news impact score of 0.20 on Accern's scale. They also assigned press coverage about the company an impact score of 46.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (0.20%). View Institutional Ownership Trends for TherapeuticsMD. Which institutional investors are selling TherapeuticsMD stock? TXMD stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC. View Insider Buying and Selling for TherapeuticsMD. How do I buy shares of TherapeuticsMD? Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is TherapeuticsMD's stock price today? One share of TXMD stock can currently be purchased for approximately $6.68. How big of a company is TherapeuticsMD? TherapeuticsMD has a market capitalization of $1.45 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe. How can I contact TherapeuticsMD? TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected] MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 187 (Vote Outperform)Underperform Votes: 138 (Vote Underperform)Total Votes: 325MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/15/2018 by MarketBeat.com StaffFeatured Article: Should you buy a closed-end mutual fund?